Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm Introduces High-Parameter Maxpar Immune Monitoring Panel for Translational and Clinical Research
Providing the industry’s first commercially available high-parameter immune monitoring solution for deep profiling of PBMC, Fluidigm brings proven mass cytometry together with innovative third-party data analysis SOUTH SAN FRANCISCO, Calif. , April 13, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation
View HTML
Toggle Summary Fluidigm Releases CFTR Next-Generation Sequencing Library Prep Assay for Use With the Juno System
SOUTH SAN FRANCISCO, Calif. , April 12, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of the Advanta™ CFTR NGS Library Prep Assay, a highly efficient and scalable next-generation sequencing (NGS) library prep workflow for sequencing of the CFTR (cystic
View HTML
Toggle Summary Fluidigm Announces Exchange of Convertible Notes
SOUTH SAN FRANCISCO, Calif. , March 13, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into separate privately negotiated transactions to exchange approximately $25.0 million in aggregate principal amount of its 2.75% Convertible Senior Notes due
View HTML
Toggle Summary Fluidigm Announces Exchange of Convertible Notes
SOUTH SAN FRANCISCO, Calif. , March 02, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into separate privately negotiated transactions to exchange approximately $125.0 million in aggregate principal amount of its 2.75% Convertible Senior Notes due
View HTML
Toggle Summary Fluidigm to Participate in Upcoming Health Care Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the company's management will participate in two upcoming investor conferences. Chris Linthwaite , President and CEO, and Vikram Jog , Chief Financial Officer, will participate in
View HTML
Toggle Summary Fluidigm Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Progress
Fluidigm Posts Sequential and Year-Over-Year Quarterly Revenue Growth 2017 Highlights Include Launch of Hyperion Imaging System, Licensing and Distribution Partnerships, Improved Balance Sheet, Double-Digit Operating Expense Reductions Mass Cytometry Research Publications Increase by More than 40%
View HTML
Toggle Summary Fluidigm to Report Q4 and Full Year 2017 Financial Results
SOUTH SAN FRANCISCO, Calif. , Jan. 25, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it will report fourth quarter and full year 2017 financial results on Thursday, February 8, 2018 , after the financial markets close.
View HTML
Toggle Summary Fluidigm Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , Dec. 21, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent directors, granted an equity award on December 15, 2017 , under Fluidigm's 2017
View HTML
Toggle Summary Fluidigm to Participate in the 29th Annual Piper Jaffray Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that Chris Linthwaite , President and CEO, and Vikram Jog , Chief Financial Officer, will participate in the upcoming 29th Annual Piper Jaffray Healthcare Conference in New York, NY .
View HTML
Toggle Summary Fluidigm Announces Third Quarter Financial Results and Operational Progress
SOUTH SAN FRANCISCO, Calif. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced financial results for the third quarter ended September 30, 2017 . Total revenue for the third quarter was $24.7 million , an increase of 12% from $22.2 million in the third quarter of
View HTML